Explore Akums at a glance, where innovation meets pharmaceutical excellence. Gain an overview of our manufacturing prowess, market presence, and contributions to the pharmaceutical landscape. Learn about our diverse business divisions, each playing a pivotal role in our growth trajectory. From stringent corporate policies prioritizing governance and ethical guidelines to our commitment to sustainable practices, every aspect of our operations reflects our dedication to integrity, transparency, and accountability.

Our commitment is to provide comprehensive insights into our company's performance, financial health, and strategic directions. Delve into our shareholder pattern, understanding the ownership distribution that influences our journey. Access our robust collection of financial statements, offering in-depth analyses of our quarterly and annual performance. Complying with industry regulations and standards, our disclosures and reports provide transparent insights into our operations, strategies, and regulatory compliance.

Investor Relations at Akums

Financial Results 2022-23 ADPL

Financial Results 2022-23

Separate Audited Financials of Subsidiaries

Financials AHL FY 2022-23

Financials Akumentis FY 2022-23

Financials Akums Lifesciences FY 2022-23

Financials Amazing FY 2022-23

Financials Malik FY 2022-23

Financials Maxcure FY 2022-23

Financials May & Baker FY 2022-23

Financials Medibox FY 2022-23

Financials Plenteous FY 2022-23

Financials Pure & Cure FY 2022-23

Financials SGA FY 2022-23

Financials Unosource FY 2022-23

Financials Upadhrish FY 2022-23

Shareholder Pattern


Code of Conduct BOD

Akums Drugs Pharmaceuticals Limited ICRA ECR

Website Disclosures

BR Sitting Fees

T&C of Appt of Independent Director

Profile of Board Members

Board of Directors

Composition of Director

Composition of Board and Committee

Profile of Directors

Mr. Sanjeev Jain

Mr. Sandeep Jain

Mr. BKS Rathore

Mr. Amit Varma

Mr. Kewal Handa

Mr. NL Kalra

Ms. Matangi Gowrishankar

Board report

Business divisions from Board report FY 2022-23


Policy Related Party Transactions signed

Policy Whistle Blower signed

Policy Determination of Materiality for disclosure

Policy Dividend Distribution signed